Revenue Breakdown
Composition ()
No data
Revenue Streams
Quest Diagnostics Inc (DGX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostic Information Services Business, accounting for 97.8% of total sales, equivalent to $2.75B. Another important revenue stream is All other operating segments. Understanding this composition is critical for investors evaluating how DGX navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Quest Diagnostics Inc maintains a gross margin of 32.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.17%, while the net margin is 9.20%. These profitability ratios, combined with a Return on Equity (ROE) of 13.69%, provide a clear picture of how effectively DGX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, DGX competes directly with industry leaders such as ASTH and NRC. With a market capitalization of $20.60B, it holds a leading position in the sector. When comparing efficiency, DGX's gross margin of 32.39% stands against ASTH's 8.53% and NRC's 57.82%. Such benchmarking helps identify whether Quest Diagnostics Inc is trading at a premium or discount relative to its financial performance.
